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Kidney allograft interstitial fibrosis and tubular atrophy
(IF/TA) is associated with a poorer renal function and
outcome. In the current clinical practice, an early
diagnosis can only be provided by invasive tests. We
aimed to investigate the association of sterile leuko-
cyturia with Banff criteria histological findings in
kidney allograft protocol biopsies. We studied 348
allograft biopsies from two different European coun-
tries performed at 8.5þ 3.5 months after transplanta-
tion. In these cases, the presence of sterile leukocyturia
(Leucþ, n¼ 70) or no leukocyturia (Leuc, n¼278) was
analyzed and related to Banff elementary lesions. Only
IF/TA was significantly different between Leucþ and
Leuc groups. IF/TA was present in 85.7% of Leucþ
and 27.7% of Leuc patients (p<0.001). IF/TA patients
had higher serum creatinine and presence of protein-
uria (p< 0.05). Independent predictors of IF/TA were
donor age, donor male sex, serum creatinine and
Leucþ (hazard ratio 18.2; 95% confidence interval,
8.1–40.7). The positive predictive value of leukocyturia
for predicting IF/TA was 85.7% whereas the negative
predictive valuewas 72.3%. These studies suggest that
leukocyturia is a noninvasive and low-cost test to
identify IF/TA. An early diagnosis may allow timely
interventional measures directed to minimize its
impact and improve graft outcome.
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Introduction
Interstitial fibrosis and tubular atrophy (IF/TA) constitute
one of the most important histopathological entities
associated with long-term renal allograft failure in protocol
biopsies taken early after renal transplantation (1,2). The
Banff grade of IF/TA correlates with lower estimated
glomerular filtration rate and higher proteinuria (3,4), and its
predictive value on outcome has been shown to be
independent from clinical and analytical parameters such
as serum creatinine, acute rejection or proteinuria (2). The
term ‘‘IF/TAwithout evidence of any specific etiology’’ was
introduced in the revised Banff 2005 classification, to
replace the previous ‘‘chronic allograft nephropathy,’’
because this name was thought to diminish attempts to
determine the underlying cause of the histologic lesions
(5,6). In fact, IF/TA seems to be the consequence of
several processes involving both alloantigen-dependent
and alloantigen-independent factors (3). Its progression
has been associated with preexisting donor damage,
degree of sensitization, cold ischemia time (CIT), clinical
and subclinical acute rejection, cyclosporine exposure and
renal calcifications (7). More recent studies have advocated
that graft implantation injury may cause an early ‘‘silent
inflammation’’ that leads to the development of IF/TA (8).
An early diagnosis of IF/TA is important given its negative
impact on renal graft prognosis and its unpredictable
development. Surveillance biopsies can diagnose IF/TA at
a preclinical stage, while graft function still remains
normal (9). Therefore, it has been advocated that they
can be used to predict the risk of subsequent graft function
deterioration, allowing early intervention designed to
decelerate or abrogate development of fibrosis and
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ultimately improve graft survival (10). However, protocol
biopsies have several limitations associatedwithmorbidity,
cost and potential for sampling error, and not all kidney
transplantation units have the human and logistical
resources to implement such a program (11). Noninvasive
diagnostic tests of IF/TA have been searched. Urinary
markers such as the protein CCL2 or the messenger RNA
levels of kidney injury molecule-1 and vimentin showed
promising results (12–14). Several recentmanuscripts have
been published reporting on the diagnosis of acute rejection
through messenger RNA amplification in the urine of some
lymphocyte-derived messages (15,16). However, none of
these expensive studies controls the presence of leuko-
cytes in the samples analyzed.
We aimed to investigate whether a routine urinalysis could
predict subclinical histopathological changes in protocol
biopsies with important impact in prognosis. Specifically,
we hypothesized that sterile leukocyturia could predict
histological findings of acute and/or chronic inflammatory
damage classified by Banff criteria.
Materials and Methods
Patient population and study design
Between January 2006 and July 2010, a total of 820 patients received a
kidney transplant at Bellvitge University Hospital and Helsinki University
Hospital. A kidney allograft biopsy was taken by protocol, after patient’s
written consent, in 422 patients at a median time of 8 months after
transplantation, as previously described (17). We retrospectively reviewed
all kidney transplant patients with a protocol biopsy who had a urinalysis
determination between 1 month before and 1 month after the protocol
biopsy.
Definition of clinical variables
Leukocyturia was determined by flow cytometry (Sysmex UF-1000i;
Sysmex Europe GmbH, Norderstedt, Germany) in a morning fresh urine
sample. The measurement range is 1–5000/mL. Leukocyturia was consid-
ered present when urinary leucocytes were >10/mL. This technique does
not provide any information about the type of leukocyte present in the urine
sample. Moreover, the following variables were evaluated at the time of
surgery: age, sex, cause of end-stage renal disease (ESRD), dialysis time,
peak/last panel reactivity antibodies, number of HLAmismatches, donor age
and sex, CIT, and immunosuppressive treatment. Regarding immunosup-
pression protocols, basiliximab was used in the case of kidneys from
extended criteria donors and thymoglobulin in high-immunological-risk
recipients. As a calcineurin inhibitor (CNI), cyclosporine was mainly used in
Helsinki while tacrolimus was preferred in Barcelona. Steroids and
mycophenolate mofetil were given to all patients. After surgery, the
following variables were recorded: time of biopsy, delayed graft function
(DGF), acute rejection, proteinuria and serum creatinine at the time of
biopsy, graft loss or death.
Kidney allograft biopsies
Protocol biopsies were performed under ultrasound guidance with an
automated biopsy gun and processed for light and immunofluorescence
microscopy. Renal lesionswere graded and diagnosed according to the 2007
Banff update of Banff 1997 diagnostic criteria (5) by local pathologists who
were unaware of leukocyturia assessment. In this classification (6), biopsies
have fibrosis if they had a Banff chronic interstitial score 1. According to
this classification, IF/TA is graded mild (grade I) when IF/TA involve<25% of
cortical area, moderate (grade II) when they affect 26–50% of cortical area
and severe (grade III) when >50% of cortical area is involved.
Statistics
All data are presented as frequencies for categorical variables or mean and
standard deviation for normally distributed continuous variables. Groups
were compared using the chi-squared test for categorical variables, t-test for
normally distributed data and nonparametric Mann–Whitney U-test for
nonnormally distributed variables. To identify independent predictors of
IF/TA, univariate and multivariate logistic regression analyses were
performed. From the probability of IF/TA predicted from these models,
sensitivity and specificity were computed to assess the predictive
performance of leukocyturia in this study. A cutoff of 0.6 in the predicted
probability (corresponding to the observed prevalence of IF/TA) was
considered to classify patients. Cumulative percent graft survival was
estimated by Kaplan–Meier analysis. All statistics were performed with
SPSS version 20.0 (IBM SPSS Statistics for Windows, Version 20.0;
Armonk, NY). The statistical significance levelwas defined as p-value< 0.05.
Results
Baseline patient characteristics
We evaluated 422 protocol kidney allograft biopsies
performed in 422 recipients (Figure S1). Seventy-four
were excluded: 7 by inadequate biopsy sample, 59 because
urinalysis was unavailable and 8 because there was a
concomitant positive urine culture. Therefore, a total of 348
biopsies were suitable for the analysis. Among the 348
patients with histological evaluation, 70 patients (20.1%)
had sterile leukocyturia (Leucþ) at the biopsy time and 278
(79.9%) had no leukocyturia (Leuc). Both groups had
similar demographic characteristics with no differences
in the etiology of ESRD (Table 1). They also had similar
transplant characteristics, namely with respect to donor
demographics, immunological compatibility, immunosup-
pressive therapy and short-term clinical outcome. Induction
therapy was given to one-third of the patients (80%
basiliximab and 20% thymoglobulin, equally in both groups).
CNI was given to nearly 90% of the patients (60%
tacrolimus and 40% cyclosporine, without differences in
Leucþ and Leuc). Ten percent of the patients were on
CNI-free protocols in both groups, either on sirolimus/
everolimus or on belatacept. No patient had diagnosis of BK
virus nephropathy. The source of kidneys from deceased
donors was always from brain death donors.
Pathological findings and laboratory determinations
according to leukocyturia
Regarding histology (Table 2), IF/TA was present in 85.7%
of Leucþ and 27.7% of Leuc patients (p< 0.001). When
all parameters of the Banff classification were analyzed
separately, only IF/TA were significantly different between
Leucþ and Leuc groups. Of note, the presence of tubular
and/or interstitial inflammation was not associated with
leukocyturia. Moreover, the addition of tubulointerstitial
inflammation to IF/TA did not increase the presence of
leukocyturia further. When the severity of IF/TA was
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analyzed,we found IF/TA grade I in 84%and grade II in 16%
of the cases without any difference between Leucþ
and Leuc groups. Moreover, there was no relationship
between the degree of IF/TA and the number of leukocytes
in urine. Although there was a trend for a higher rate of
clinical acute rejections in the Leucþ group (Table 1), there
was no statistically significant difference in the proportion
of acute rejection or borderline changes in both groups
(Table 2). On the other hand, the Leucþ group had a higher
serum creatinine at the time of biopsy (p¼ 0.019). There
were also a higher proportion of the Leucþ patients with
proteinuria (Table 2).
Table 2: Main differences in histological and laboratory findings between patients with and without leukocyturia
All patients (N¼348) With leukocyturia (N¼70) Without leukocyturia (N¼278) p-Value
Time of biopsy (days, SD) 263.9 (105.8) 276.6 (121.3) 260.7 (101.5) 0.261
Subclinical AR (%) 29 (8.3) 6 (8.6) 23 (8.3) 0.881
Borderline changes (%) 118 (33.9) 23 (32.9) 95 (34.2) 0.835
IF/TA (%) 137 (39.4) 60 (85.7) 77 (27.7) <0.001
g (%) 42 (12.3) 35 (12.8) 7 (10.3) 0.577
i (%) 126 (36.5) 24 (34.8) 102 (37.0) 0.737
t (%) 75 (21.8) 14 (20.6) 61 (22.1) 0.787
v (%) 6 (1.7) 2 (2.9) 4 (1.5) 0.413
aah (%) 60 (17.5) 16 (23.5) 44 (16.0) 0.143
cg (%) 4 (1.2) 1 (1.5) 3 (1.1) 0.794
ci (%) 154 (44.6) 57 (82.6) 97 (35.1) <0.001
ct (%) 159 (46.1) 52 (75.4) 107 (38.8) <0.001
mm (%) 28 (8.6) 7 (10.6) 21 (8.0) 0.507
Proteinuria, >0.15 g/day (%) 119 (36.2) 34 (50.7) 85 (32.4) 0.005
Proteinuria, >0.5 g/day (%) 21 (6.4) 8 (11.9) 13 (5.0) 0.037
sCreatinine (mmol/L; SD) 120.3 (35.9) 129.3 (39.1) 118.0 (34.8) 0.019
For g, i, t, v, aah, cg, ci, ct, mm, % means the percentage of cases with the value of the corresponding variable above 0.
aah, arteriolar hyaline thickening; AR, acute rejection; cg, allograft glomerulopathy; ci, interstitial fibrosis; ct, tubular atrophy; g, glomerular
inflammation; i, interstitial inflammation; IF/TA, interstitial fibrosis and tubular atrophy; mm,mesangial matrix increase; t, tubulitis; v, intimal
arteritis.
Statistically significant p-values in bold.
Table 1: Demographic and clinical data
All patients (N¼348) With leukocyturia (N¼70) Without leukocyturia (N¼278) p-Value
Cause of ESRD (%)
Diabetes 60 (17.2) 11 (18.3) 49 (17.6) –
Glomerular 97 (27.9) 25 (35.7) 72 (25.9) –
Interstitial 30 (8.6) 2 (2.9) 28 (10.1) –
Polycystic kidney disease 64 (18.4) 15 (21.4) 49 (17.6) –
Vascular 22 (6.3) 7 (10) 14 (5.4) –
Other 75 (21.5) 10 (14.3) 65 (23.4) 0.09
Recipient sex (male/female) 230/118 11/13 69/26 0.29
Recipient age (mean, SD) 49.19 (SD 12.8) 49.82 (SD 13.5) 49.04 (SD 12.6) 0.65
Donor sex (male/female) 208/140 40/30 168/110 0.62
Donor age (mean, SD) 48.3 (SD 14.2) 50.03 (SD 13.5) 47.87 (SD 14.4) 0.26
Retransplantation (%) 31 (8.9) 5 (7.2) 26 (9.4) 0.72
DD/LD 334/14 66/4 268/10 0.42
Previous acute rejection (%) 60 (17.2) 17 (24.3) 43 (15.5) 0.08
Dialysis time (mean, SD) 27.32 (SD 24.2) 25.71 (SD 23.0) 27.7 (SD 24.5) 0.53
Induction therapy (%) 120 (34.6) 24 (34.3) 96 (34.7) 0.95
CNI (%) 312 (89.7) 62 (88.6) 250 (89.9) 0.74
HLA-A MM (SD) 1.37 (0.6) 1.54 (0.6) 1.33 (0.6) 0.11
HLA-B MM (SD) 1.35 (0.5) 1.38 (0.6) 1.35 (0.5) 0.83
HLA-DR MM (SD) 0.73 (0.6) 0.66 (0.6) 0.75 (0.6) 0.24
Cold ischemia time (SD) 18.85 (5.9) 18.5 (7.2) 18.9 (5.6) 0.54
DGF (%) 116 (33.3) 25 (35.7) 91 (32.7) 0.64
CNI, calcineurin inhibitor; DD, deceased donor; DGF, delayed graft function; ESRD, end-stage renal disease; LD, living donor; MM,
mismatch; SD, standard deviation.
p-Value by chi-squared test to the overall relationship.
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Variables associated with IF/TA in kidney allograft
protocol biopsies
The overall IF/TA prevalence in our study population was
39.4%. These patients more frequently received kidneys
from older and/or male donors (Table 3). The antecedent of
clinical acute rejection was also associated with IF/TA.
Regarding laboratory determinations, IF/TA patients had
higher serum creatinine and presence of proteinuria and
leukocyturia (Table 3). On the other hand, the significant
variables associated with IF/TA in the univariate analysis
were included in a multivariate logistic regression model,
together with other clinical variables that may have an
impact on the association between leukocyturia and IF/TA
(e.g. DGF). Donor age, donor male sex, serum creatinine
and particularly Leucþ (hazard ratio [HR] 18.2, 95%
confidence interval [CI], 8.1–40.7) were predictors of IF/TA.
Therefore, leukocyturia was associated with a higher risk to
observe IF/TA in the kidney allograft protocol biopsy (Table 4).
The specificity of leukocyturia for predicting IF/TAwas 95.3%
whereas the sensitivitywas 44%. Also, its positive predictive
value (PPV) was 85.7% and negative predictive value (NPV)
was 72.3%.
Leukocyturia and graft survival
The mean follow-up (from transplantation until graft loss or
censored at July 12, 2012) was 5.1 2.1 years, rather short
to observemajor differences. Nevertheless, there is a trend
to poor graft survival in patients showing IF/TA and
inflammation in the protocol biopsy (Figure 1A). Leukocy-
turia had no effect on patient and graft survival (p¼ 0.98,
log-rank test). Moreover, the addition of leukocyturia to
pathological findings was not associated with any signifi-
cant change in graft survival (Figure 1B).
Discussion
In our study, we analyzed the relationship between a
classical urine analysis and the Banff classification and
Table 3: Variables associated with IF/TA in kidney allograft protocol biopsies
All patients (N¼348) With IF/TA (N¼137) Without IF/TA (N¼211) p-Value
Recipient sex (male/female) 230/118 96/41 134/77 0.206
Recipient age (mean, SD) 49.1 (12.8) 50.3 (13.1) 48.5 (12.5) 0.210
Donor sex (male/female) 208/140 92/45 116/95 0.024
Donor age (mean, SD) 48.3 (14.2) 51.1 (14.1) 46.5 (14.0) 0.003
Retransplantation (%) 31 (9.0) 13 (9.5) 18 (8.6) 0.931
DD/LD 334/14 132/5 202/9 0.775
Previous acute rejection (%) 60 (17.2) 33 (24.1) 27 (12.8) 0.006
Dialysis time (mean, SD) 27.3 (24.2) 26.3 (25.1) 28.0 (23.6) 0.537
CNI (%) 312 (89.7) 118 (86.1) 194 (91.9) 0.082
HLA-A MM (SD) 1.37 (0.6) 1.45 (0.6) 1.28 (0.6) 0.125
HLA-B MM (SD) 1.35 (0.5) 1.37 (0.5) 1.33 (0.6) 0.723
HLA-DR MM (SD) 0.73 (0.6) 0.78 (0.6) 0.70 (0.6) 0.185
Cold ischemia time (SD) 18.8 (5.9) 18.8 (6.0) 18.9 (5.9) 0.819
DGF (%) 116 (33.3) 48 (35.0) 68 (32.2) 0.587
Leukocyturia (%) 70 (20.1) 60 (43.8) 10 (4.7) <0.001
Proteinuria, >0.15 g/day (%) 119 (36.2) 63 (48.8) 56 (28.0) <0.005
Proteinuria, >0.5 g/day (%) 21 (6.4) 12 (9.3) 9 (4.5) 0.082
sCreatinine (mmol/L; SD) 120.2 (35.9) 130.2 (38.2) 113.8 (32.9) <0.005
CNI, calcineurin inhibitor; DD, deceased donor; DGF, delayed graft function; IF/TA, interstitial fibrosis and tubular atrophy; LD, living donor;
MM, mismatch; SD, standard deviation.
Statistically significant p-values in bold.
Table 4: Logistic regression analysis for IF/TA predictors
Covariates
Univariate Multivariate
HR 95% CI p-Value HR 95% CI p-Value
Donor sex Male vs. female (ref) 1.76 (1.07, 2,62) 0.024 2.68 (1.48, 4.86) 0.001
Donor age (year) 1.024 (1.008, 1.041) 0.003 1.027 (1.004, 1.049) 0.018
Acute rejection Presence vs. absence (ref) 2.16 (1.23, 3.80) 0.007 2.01 (0.98, 4.12) 0.056
DGF Presence vs. absence (ref) 1.13 (0.72, 1.79) 0.58 0.73 (0.40, 1.35) 0.321
Proteinuria Presence vs. absence (ref) 2.46 (1.55, 3.90) 0.0001 1.67 (0.953, 2.914) 0.073
Leukocyturia Presence vs. absence (ref) 15.7 (7.63, 32.2) <0.0001 18.2 (8.13, 40.7) <0.0001
1 year sCreatinine (mmol/L) 1.013 (1.007, 1.020) <0.0001 1.010 (1.001, 1.019) 0.032
Proteinuria is >0.15 g/day.
CI, confidence interval; DGF, delayed graft function; HR, hazard ratio; IF/TA, interstitial fibrosis and tubular atrophy.
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provide evidence that leukocyturia can be useful in
predicting IF/TA in early protocol biopsies.
Sterile leukocyturia, defined as the presence of leukocytes
in the urine without bacterial growth on conventional
immersion culture media, has been associated with
interstitial nephritis, nephrolithiasis, uroepithelial tumors
and infectionwith atypical organisms (18–20). Interestingly,
Baquero and Santiago-Delpin (21) have also described an
association of sterile leukocyturia with high serum creati-
nine and worse allograft outcome in kidney transplant
patients, although these authors did not report any
histological assessment. Although we did not observe
any effect of leukocyturia on graft survival, probably
because of the relatively short follow-up, our results
were in agreement with Baquero and Santiago-Delpin (21)
because leukocyturia was associated with high serum
creatinine and presence of proteinuria.
Kidney interstitial fibrosis is defined by the accumulation of
collagen and related molecules in the renal interstitium.
Tubular atrophy is usually associated with interstitial
Figure 1: Death-censored graft survival according histological findings. (A) In the Kaplan–Meier analysis, the association of IF/TAwith
inflammation shows a trend toward poor graft survival, although the mean follow-up is relatively short (5.12.1 years) to observe high
number of events. (B) The presence or absence of leukocyturia was not associated with any significant change in graft survival. p-Values
were obtained by log-rank test. There were eight patients with leukocyturia and normal biopsy and three cases with leukocyturia and
inflammation. These groups are not included in the Kaplan–Meier analysis due to the small number and the absence of events. IF/TA,
interstitial fibrosis and tubular atrophy.
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fibrosis, although it probably has different mechanisms,
being defined as loss of tubular specialized transport and
metabolic capacity (22). IF/TA is thought to result from the
orchestration of multiple cell types: tubular cells, renal
vasculature cells and inflammatory cells, including lympho-
cytes, monocyte/macrophages, mast cells and dendritic
cells (22). The renal tubular and endothelium cells are
thought to undergo transitional changes into a mesenchy-
mal phenotype, responsible for the production of fibrosis
and extracellular matrix deposition. Inflammatory cells
seem to mediate the epithelial to mesenchymal transition
(22) and thismay thus explainwhywe found leukocyturia to
be associated with IF/TA.
Recently, the Mayo Clinic group reported data of almost
600 patients with 1- and 5-year protocol biopsies (23).
During the first posttransplant year, 53% had fibrosis, but
only 23% of patients with mild fibrosis progressed to more
severe forms at 5 years. Similarly, in our study, we
described 39.4% prevalence of IF/TA at 6–10 months
posttransplantation. There are several well-known risk
factors for IF/TA (3). As an example, in a series of 688
protocol biopsies performed in 258 patients, Schwarz et
al (24) reported that the risk factors for IF/TA at 26 weeks
after transplantation were GFR at 3 months, previous acute
rejection and nephrocalcinosis in a previous biopsy. In our
study, IF/TA was associated with donor age and sex and
acute rejection, in accordance to previous studies. A higher
donor age and male sex probably represent baseline
damage already present in the allograft at the time of
implantation. However, we could not confirm this notion
due to the lack of preimplantation kidney biopsy assess-
ment in our study. An acute rejection episode before the
protocol biopsy suggests an alloimmune injury that healed
into IF/TA. Interestingly, a third of patients with IF/TA also
had tubulitis and more than 40% had interstitial inflamma-
tion, which represents ongoing acute damage on chronic
tubular and interstitial lesions. We found IF/TA with
inflammation was associated with a poorer outcome in
our study, as previously described (25). Recently, the
current apparently less severe and less progressive nature
of early IF/TA in the absence of inflammation led some
authors to compare it to the process of wound healing
that evolves into mild and stable lesions (26). However,
although these chronic lesions probably have a lower
impact on kidney allograft and patient outcome than
previously thought and possibly lower than other factors
like acute rejection, this does not mean that they have no
impact at all. In fact, in our study, patients with IF/TA had
higher serum creatinine and proteinuria at the time of
protocol biopsy than patients without IF/TA. A larger
number of cases and a higher follow-up might have shown
a difference in graft and patient survival.
Early identification of IF/TA is important in order to
implement strategies that can slow its progression and
ideally reverse its development. Several studies have
shown that progression of IF/TA is related to immunosup-
pression (27,28) and Gelens et al (4) even suggested that it
should be guided according to the grade of IF/TA at
preimplantation biopsy. Although there is still not enough
evidence, there are some surrogate markers that point
to a beneficial effect of angiotensin-converting enzyme
inhibitor/angiotensin receptor blocker in the treatment of
IF/TA (29). Along these lines, it is important to develop
biomarkers of kidney allograft lesions. For instance,
Suthanthiran et al (15) reported a urinary test that accurately
diagnoses acute rejection of kidney transplants by just
measuring three genetic molecules in a urine sample.
Nowadays, the use of omics-technologies in further
refining the diagnostic criteria and predict outcomes is
being actively explored in both experimental and clinical
settings (30,31). The study of the genomic profile (geno-
mics) and proteins (proteomics) revealed that the genes
and proteins more commonly expressed in patients with
IF/TA were those related to immune response, inflamma-
tion and matrix deposition (32–34). Transcriptomics (the
study of gene transcripts) associated areas of IF/TA with
distinct secondary inflammation patterns: lymphoid aggre-
gates, B cell and plasma cell transcripts (35), mast cell
transcripts (36), and FoxP3 mRNA (37). Although these
results are promising, they are complex, not accessible in
daily practice and time-consuming. Although many of
these studies are seeking leukocyte products, surprisingly
none of them control the mere presence of leukocytes in
the samples analyzed. Our study suggests that it is feasible
to overcome the need for a biopsy in patients with
leukocyturia (PPV of 85.7%), though it should not be
considered as a fair screening test since its sensitivity is
44%. Leukocyturia could be a highly specific test for IF/TA,
since the estimated probability of a positive test of
leukocyturia among patients without IF/TA is low (100
specificity¼5%). However, the NPV of 72.3% suggests
that it may not be possible to avoid the biopsy to diagnose
IF/TA in patients without leukocyturia. The predictive
performance of leukocyturia should be validated in an
independent data set. On the other hand, it would also be
interesting to explore a study looking at the measurement
variability between institutions and comparing different
techniques (flow cytometry, urinary dipstick and standard
urinary sediment).
Our study has some limitations associated with its
retrospective design. Nevertheless, we analyzed a consid-
erable number of patients from two different European
countries, which strengthens our conclusions and mini-
mizes the impact of possible confounders. In addition,
although leukocyturia was useful for IF/TA detection, it was
useless for identifying those patients with IF/TA who were
at risk of graft failure. Urinary infections with atypical
organisms have not been systematically excluded as a
cause of sterile leukocyturia.
In conclusion, in the current-omics era, our results suggest
that classical urinalysis still provides valuable clinical
information for the follow-up of kidney allograft recipients,
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although prospective studies on the assessment of the
type of leukocytes in urine are necessary to validate our
retrospective results. Sterile leukocyturia might be an
accessible, low-cost marker of IF/TA.
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